NASDAQ: NBP
Novabridge Biosciences Stock Ownership - Who owns Novabridge Biosciences?

Insider buying vs selling

Have Novabridge Biosciences insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cong Claire XuSVP Clinical Development2026-06-013,494$3.94
$13.77kSell
Sean Wuxiong CaoChief Business Development Officer and Director2026-05-1421,399$1.99
$42.58kSell
Mark Arnold HaglerPresident and Chief Commercial Officer2026-04-24230,000$2.51
$577.30kBuy

1 of 1

NBP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NBP insiders and whales buy or sell their stock.

NBP Shareholders

What type of owners hold Novabridge Biosciences stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Wei Fu11.49%30,499,699$45.75MInsider
Janus Henderson Group PLC2.27%6,032,650$9.05MInstitution
Hhlr Advisors Ltd2.25%5,980,568$8.97MInstitution
Morgan Stanley1.45%3,838,198$5.76MInstitution
Siren LLC1.13%3,000,000$4.50MInstitution
Aihc Capital Management Ltd0.85%2,262,933$3.39MInstitution
Point72 Asset Management LP0.52%1,389,403$2.08MInstitution
Candriam Sca0.43%1,132,563$1.70MInstitution
Adage Capital Partners GP LLC0.38%1,000,000$1.50MInstitution
Xiaofan Neo Zhang0.33%874,000$1.31MInsider

1 of 3

NBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NBP11.05%12.11%Net BuyingNet Buying
TTRX1.55%58.04%Net Buying
YDES0.23%3.64%
DTIL36.73%63.27%Net Selling
IPHA0.20%0.00%

Novabridge Biosciences Stock Ownership FAQ

Who owns Novabridge Biosciences?

Novabridge Biosciences (NASDAQ: NBP) is owned by 11.05% institutional shareholders, 12.11% Novabridge Biosciences insiders, and 76.84% retail investors. Wei Fu is the largest individual Novabridge Biosciences shareholder, owning 30.50M shares representing 11.49% of the company. Wei Fu's Novabridge Biosciences shares are currently valued at $45.75M.

If you're new to stock investing, here's how to buy Novabridge Biosciences stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.